Form 4: Senseonics CCO Brian Hansen Receives Equity Grant

Senseonics Holdings, Inc. Chief Commercial Officer Brian Hansen was granted 90,253 restricted stock units and 124,193 stock options.

Summary

• Brian Hansen, Chief Commercial Officer of Senseonics Holdings, Inc., received a grant of 90,253 restricted stock units (RSUs).
• The RSU grant vests in eight equal installments starting June 15, 2026, with subsequent installments every six months.
• Hansen was also granted 124,193 employee stock options with an exercise price of $5.54 per share.
• The stock options vest in 48 equal monthly installments beginning May 19, 2026.
• The total beneficial ownership for the reporting person following these transactions is 132,357 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding executive compensation, which is neutral in terms of immediate market impact.

Positives

• Equity grants align the interests of the Chief Commercial Officer with those of shareholders.
• The multi-year vesting schedule for both RSUs and options encourages long-term retention of key management.

Negatives

• The issuance of new equity awards results in potential dilution for existing shareholders.

Risks

• Vesting of equity is contingent upon the reporting person's continuous service with the issuer.
• The value of the equity grants is subject to market volatility and the future performance of the company's common stock.

Future Outlook

The filing does not provide forward-looking financial guidance, focusing solely on executive compensation and equity ownership changes.

Industry Context

StockSavvy.ai notes that equity-based compensation remains a standard practice in the medical technology sector to attract and retain executive talent, particularly for companies in the growth or commercialization phase like Senseonics.

Comparison to Industry Standards

• The use of multi-year vesting schedules for executive equity is consistent with standard corporate governance practices in the U.S. biotech and medtech industries.
• The grant of both RSUs and stock options is a common dual-incentive structure used by peers to balance immediate equity ownership with performance-based upside.

Stakeholder Impact

• Shareholders may experience minor dilution due to the issuance of new equity awards.

Next Steps

• Vesting of the first RSU installment on June 15, 2026.
• Ongoing monthly vesting of stock options.

Key Dates

Keywords

Senseonics, SENS, Form 4, Insider Trading, Equity Compensation, Chief Commercial Officer